Welcome to our dedicated page for Alps Group SEC filings (Ticker: ALPS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alps Group Inc filings document the company's foreign private issuer current-report disclosures following its completed SPAC business combination and public-company transition. Form 6-K reports furnish material-event updates, press releases, governance changes, board appointments, committee service, executive leadership appointments, employment agreement terms, capital-structure matters, and security-structure disclosures.
The filing record also covers company-specific biotechnology disclosures, including peer-reviewed case reports involving autologous Natural Killer cell infusions produced with an in-house culture protocol and CELESOME(+) exosome-related development activities. These documents frame Alps Group's formal disclosures around clinical-program communications, corporate governance, material agreements, and operating and financial reporting categories.
Alps Group Inc received a Nasdaq notice that it is not in compliance with the exchange’s minimum bid price rule, which requires a closing bid of at least $1.00 per share for its ordinary shares. The shares traded below this level for 30 consecutive business days.
The notice does not immediately affect listing, trading, operations, or financial condition. Alps Group has 180 calendar days, until November 11, 2026, to regain compliance and may qualify for an additional 180 days if certain listing standards are met. The company is evaluating options, including a potential reverse stock split, but there is no assurance it will regain compliance, and the shares could ultimately face delisting if it cannot cure the deficiency.
Alps Group Inc director Lee Hee Hang has filed an initial ownership report showing a holding of 20,000 Ordinary Shares. The filing is a Form 3, which establishes Lee’s starting equity position in the company and does not disclose any recent share purchases or sales.
Alps Group Inc has appointed Mr. Hee H. Lee to its Board of Directors, effective April 17, 2026, expanding the Board from five to six members. He is considered independent under Nasdaq rules and is expected to join both the Audit Committee and the Compensation Committee.
Mr. Lee is a New York-licensed Certified Public Accountant with more than three decades of public accounting and advisory experience, including as a Partner at Ernst & Young LLP and long-standing advisory work with the International Swaps and Derivatives Association. The company operates an integrated biotechnology and healthcare platform focused on predictive, preventive, and precision medicine.
Alps Group Inc officer Poh Chit Laa has filed an initial statement of beneficial ownership. The filing shows direct ownership of 2,000 Ordinary Shares as of March 18, 2026. This Form 3 does not report any recent purchase, sale, or option exercise, only the existing share position.
Alps Group Inc director Chua Boon Ping filed an initial ownership report showing a direct holding of 150,000 Ordinary Shares. This Form 3 does not record a new purchase or sale but establishes the director’s existing equity stake and confirms direct ownership of these shares.
Alps Group Inc director Chew Yoke Ling has filed an initial ownership report showing a substantial equity stake in the company. The Form 3 discloses direct ownership of 6,882,720 Ordinary Shares as of the reported date. This filing records existing holdings and does not reflect any new buy or sell transaction.
Alps Group Inc executive Cheing Lye-Ping, the Chief Financial Officer, has filed an initial statement of beneficial ownership on Form 3. The data provided shows no reported purchases, sales, gifts, tax withholdings, restructurings, or derivative exercises, indicating no insider trading activity is disclosed in this excerpt.
Alps Group Inc director Mohamed Suleiman bin has filed an initial ownership report on Form 3. This filing establishes his status as a director of the company and indicates that there are currently no reportable transactions or derivative positions listed in the submission.
Alps Group Inc executive Manickam Ravichandran, the Chief Scientific Officer, has filed an initial insider ownership report. The filing shows direct ownership of 20,000 Ordinary Shares, establishing his reported equity stake in the company but not reflecting any recent buy or sell transaction.
Alps Group Inc executive Low Wei Sim, the Chief Operating Officer, has filed an initial ownership report showing a direct holding of 821,083 Ordinary Shares. This filing is a Form 3, which records the officer’s existing stake and does not reflect a new buy or sell transaction.